Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
Abstract Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here,...
Saved in:
Main Authors: | Richard Buus, Zsolt Szijgyarto, Eugene F. Schuster, Hui Xiao, Ben P. Haynes, Ivana Sestak, Jack Cuzick, Laia Paré, Elia Seguí, Nuria Chic, Aleix Prat, Mitch Dowsett, Maggie Chon U. Cheang |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/ab6604a1505e46ae8d5a30ae6561a42c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017) -
Titchmarsh's Theorem for the Dunkl transform in the space L²(Rd,ωk(x)dx)
by: Daher,Radouan, et al.
Published: (2014) -
EndoTHeF: Endoluminal Treatment of Hemorrhoids with Foam
by: Maurizio Ronconi, et al.
Published: (2018) -
Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype
by: Haifa Xia, et al.
Published: (2017) -
Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs)
by: Shevtsov M, et al.
Published: (2018)